---
title: Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal
  docetaxel-resistant prostate cancer
date: '2024-05-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38750263/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240516181522&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Docetaxel (DX) serves as a palliative treatment option for metastatic
  prostate cancer (PCa). Despite initial remission, acquired DX resistance is inevitable.
  The mechanisms behind DX resistance have not yet been deciphered, but a mesenchymal
  phenotype is associated with DX resistance. Mesenchymal phenotypes have been linked
  to metabolic rewiring, obtaining most ATP production by oxidative phosphorylation
  (OXPHOS) powered substantially by glutamine (Gln). Likewise, Gln is known to play
  ...
disable_comments: true
---
Docetaxel (DX) serves as a palliative treatment option for metastatic prostate cancer (PCa). Despite initial remission, acquired DX resistance is inevitable. The mechanisms behind DX resistance have not yet been deciphered, but a mesenchymal phenotype is associated with DX resistance. Mesenchymal phenotypes have been linked to metabolic rewiring, obtaining most ATP production by oxidative phosphorylation (OXPHOS) powered substantially by glutamine (Gln). Likewise, Gln is known to play ...